Application of specnuezhenide in preparation of medicine for treating neovascular diseases

A kind of technology of new blood vessel, special privet glycoside, applied in the field of medicine

Active Publication Date: 2017-03-29
SICHUAN JISHENGTANG PHARMLS
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is currently no literature reporting ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of specnuezhenide in preparation of medicine for treating neovascular diseases
  • Application of specnuezhenide in preparation of medicine for treating neovascular diseases
  • Application of specnuezhenide in preparation of medicine for treating neovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1 privetin to CoCl 2 Induced effects of VEGF overexpression

[0024] Experimental materials: DMEM / F12 medium (batch number 30-2006, Invitrogen Company); CoCl 2 (Lot No. 231-589-4, Sigma Company); 96-well plate (Lot No. 13313040, Corning Company); 20 × PBS solution (Lot No. 13112593Z, Shanghai Sangon Biological Company); Human VEGF Elisa kit (human vascular endothelial cell growth factor enzyme Linked immunoassay kit, batch number DVE00, R&D company); teruzhenin (batch number 111926-201102, specification: 20mg / bottle), provided by China Institute for the Identification of Pharmaceutical and Biological Products.

[0025] Take retinal pigment epithelial-19 cells (ARPE-19) in the logarithmic growth phase, and press 8×10 3 cells / well were inoculated in 96-well plate, and divided into 4 groups, namely, blank group, model group and teruzhenin group, with 3 multiple wells in each group; after the cells adhered to the wall, the old medium was discarded and replaced ...

Embodiment 2

[0030] Example 2 Effects of terra privetin on hypoxia-induced retinal neovascularization

[0031] Experimental materials: Tris-maleic acid buffer (specification: 100mL, batch number JR02108, Shanghai Junrui Biotechnology Co., Ltd.); lead nitrate (specification: 500g, batch number 20130118, Chengdu Kelong Chemical Reagent Factory); magnesium chloride (specification: 500g, batch number 20130409, Chengdu Kelong Chemical Reagent Factory); glycerol buffer (specification: 500mL, batch number F20090908, Sinopharm Chemical Reagent Co., Ltd); Conbercept Ophthalmic Injection (specification: 10mg / ml, 0.2ml / Batch, batch number 20110610B, Chengdu Kanghong Biotechnology Co., Ltd.); privetin (batch number 111926-201102, specification: 20mg / bottle), provided by the National Institute of Pharmaceutical and Biological Products; SD pregnant rat, SPF grade, certificate number: SCXK (Sichuan) 2013-24, all provided by Chengdu Dashuo Biotechnology Co., Ltd.

[0032] Model establishment and group a...

Embodiment 3

[0040] Embodiment 3 terutrusin is to CoCl 2 Induced effects of HIF-1α overexpression

[0041] Experimental materials: YC-1 (specification: 10mg / cartridge, lot number ab120915, abcam company); DMEM / F12 medium (lot number 30-2006, Invitrogen company); CoCl 2 (Lot No. 231-589-4, Sigma Company); 96-well plate (Lot No. 13313040, Corning Company); 20 × PBS solution (Lot No. 13112593Z, Shanghai Sangon Biological Company); BCA kit (Lot No. MK165953, Thermo Scientific Company); Tinutrusin (batch number 111926-201102, specification: 20mg / bottle), provided by China National Institute of Pharmaceutical and Biological Products; protein lysate: (containing 50mmol / L Tris-HCl, 1% Triton X-100, 0.2% deoxycholesterol sodium phosphate, 0.2% SDS, 1mmol / L sodium edetate, 1mM sulfonyl fluoride, 1mmol / L PMSF, 10μg / ml leupeptin); 5× loading buffer (containing 250mM pH6.8Tris- HCl, 10% SDS, 0.5% bromophenol blue, 50% glycerol, 5% β-mercaptoethanol); tetramethylethylenediamine (TEMED; specification: ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of specnuezhenide in preparation of medicine for treating neovascular diseases. The applicant discovers from a lot of researches that specnuezhenide has a remarkable inhibition function on vascular endothelial growth factors (VEGF), can remarkably improve hypoxia-induced pathological phenomena like circuity, expansion and deformation of retina new vessels, and can decrease the occupied area of the new vessels, so that specnuezhenide can effectively inhibit formation of eye new vessels and has the function for treating neovascular diseases. The invention provides application of specnuezhenide in preparation of medicine for treating diseases relevant to HIF-1 alpha high expression.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of privetin in the preparation of medicines for treating neovascular diseases. Background technique [0002] Angiogenesis is the process of sprouting new blood vessels from existing blood vessels, which is related to the migration and proliferation of vascular endothelial cells. It has been found that new blood vessel formation can occur in pathological conditions such as trauma, ischemia, inflammation, tissue hypoxia, tumor growth, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, and psoriasis. Although there are differences in the origin and early pathology of various neovascular diseases, the pathological process of neovascularization is the same, and they all go through two stages: one is the stage of tissue hypoxia, and the other is to improve the nutrition of the tissue and overcome the state of tissue hypoxia. The stage of abnorma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P35/00A61P35/04A61P27/02A61P27/06A61P9/10A61P27/10
CPCA61K31/7048
Inventor 柯潇
Owner SICHUAN JISHENGTANG PHARMLS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap